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Summary
Background—The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 
months of follow-up have been published previously. Herein, we report the final results from the 
same trial, including the efficacy of a booster dose.
Methods—From March 27, 2009, until Jan 31, 2011, children (age 5–17 months) and young 
infants (age 6–12 weeks) were enrolled at 11 centres in seven countries in sub-Saharan Africa. 
Participants were randomly assigned (1:1:1) at first vaccination by block randomisation with 
minimisation by centre to receive three doses of RTS,S/AS01 at months 0, 1, and 2 and a booster 
dose at month 20 (R3R group); three doses of RTS,S/AS01 and a dose of comparator vaccine at 
month 20 (R3C group); or a comparator vaccine at months 0, 1, 2, and 20 (C3C [control group]). 
Participants were followed up until Jan 31, 2014. Cases of clinical and severe malaria were 
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captured through passive case detection. Serious adverse events (SAEs) were recorded. Analyses 
were by modified intention to treat and per protocol. The coprimary endpoints were the occurrence 
of malaria over 12 months after dose 3 in each age category. In this final analysis, we present data 
for the efficacy of the booster on the occurrence of malaria. Vaccine efficacy (VE) against clinical 
malaria was analysed by negative binomial regression and against severe malaria by relative risk 
reduction. This trial is registered with ClinicalTrials.gov, number NCT00866619.
Findings—8922 children and 6537 young infants were included in the modified intention-to-
treat analyses. Children were followed up for a median of 48 months (IQR 39–50) and young 
infants for 38 months (34–41) after dose 1. From month 0 until study end, compared with 9585 
episodes of clinical malaria that met the primary case definition in children in the C3C group, 
6616 episodes occurred in the R3R group (VE 36·3%, 95% CI 31·8–40·5) and 7396 occurred in 
the R3C group (28·3%, 23·3–32·9); compared with 171 children who experienced at least one 
episode of severe malaria in the C3C group, 116 children experienced at least one episode of 
severe malaria in the R3R group (32·2%, 13·7 to 46·9) and 169 in the R3C group (1·1%, –23·0 to 
20·5). In young infants, compared with 6170 episodes of clinical malaria that met the primary case 
definition in the C3C group, 4993 episodes occurred in the R3R group (VE 25·9%, 95% CI 19·9–
31·5) and 5444 occurred in the R3C group (18·3%, 11·7–24·4); and compared with 116 infants 
who experienced at least one episode of severe malaria in the C3C group, 96 infants experienced 
at least one episode of severe malaria in the R3R group (17·3%, 95% CI –9·4 to 37·5) and 104 in 
the R3C group (10·3%, –17·9 to 31·8). In children, 1774 cases of clinical malaria were averted per 
1000 children (95% CI 1387–2186) in the R3R group and 1363 per 1000 children (995–1797) in 
the R3C group. The numbers of cases averted per 1000 young infants were 983 (95% CI 592–
1337) in the R3R group and 558 (158–926) in the R3C group. The frequency of SAEs overall was 
balanced between groups. However, meningitis was reported as a SAE in 22 children: 11 in the 
R3R group, ten in the R3C group, and one in the C3C group. The incidence of generalised 
convulsive seizures within 7 days of RTS,S/AS01 booster was 2·2 per 1000 doses in young infants 
and 2·5 per 1000 doses in children.
Interpretation—RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 
3–4 year period in young infants and children when administered with or without a booster dose. 
Efficacy was enhanced by the administration of a booster dose in both age categories. Thus, the 
vaccine has the potential to make a substantial contribution to malaria control when used in 
combination with other effective control measures, especially in areas of high transmission.
Funding—GlaxoSmithKline Biologicals SA and the PATH Malaria Vaccine Initiative.
Introduction
Substantial progress has been made in malaria control during the past decade, but the burden 
of malaria in Africa remains high.1 A malaria vaccine could be an important complement to 
existing control measures and could help reduce morbidity and mortality in children.
RTS,S/AS01 is a recombinant protein candidate malaria vaccine that targets the 
circumsporozoite protein of Plasmodium falciparum, expressed by the malaria parasite at the 
pre-erythrocytic stage, in which part of the circumsporozoite sequence is coexpressed with 
fused and free hepatitis B surface antigen2,3 and formulated with the AS01 adjuvant. 
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Previous studies have established the ability of RTS,S/AS01 to provide protective immunity.
4–6
We undertook a phase 3, double-blind (observer-blind), individually randomised, controlled 
trial to assess the efficacy and safety of RTS,S/AS01. Study results up to 18 months of 
follow-up have been reported previously.7–9 The coprimary endpoints of efficacy to clinical 
malaria over the first 12 months after dose 3 were 55·8% (97·5% CI 50·6–60·4) in children 
aged 5–17 months and 31·3% (23·6–38·3) in infants aged 6–12 weeks.7–9 Protection against 
clinical and severe malaria was noted in both children and young infants during the first 12 
months after vaccination, but protection waned over time in both age categories.9 Herein, we 
report the efficacy, immunogenicity, and safety of RTS,S/AS01 and the number of cases 
averted by the use of the vaccine in children and young infants followed up to the end of the 
trial, including findings in those who received a booster dose of vaccine.
Methods
Study design and participants
We undertook this phase 3, double-blind, observer-blind, individually randomised controlled 
trial between March 27, 2009, and Jan 31, 2014, at 11 centres in seven countries in sub-
Saharan Africa that are situated in areas with different intensities of malaria transmission 
(appendix p 18). Trial methods have been reported previously,7–9,10 and are described in 
the appendix (pp 4–13). We initially designed this trial to assess vaccine efficacy (VE), 
safety, and immunogenicity during 32 months of follow-up, but the protocol was amended 
before month 32, on Dec 1, 2010, to extend the follow-up period to Dec 31, 2013 (median 
follow-up 48 months for children and 38 months for young infants). Parents or legally 
authorised representatives of all participants provided written or thumb printed and 
witnessed informed consent at enrolment to the primary study and to the extension. Access 
to an insecticide-treated bednet was optimised for all screened children. Net use and 
condition were assessed during protocol-specified home visits done at month 13, month 31, 
and 1 month before study end.
The trial protocol was approved by the ethical review board at each study centre and partner 
institution and by the national regulatory authority in each country (appendix p 44–45) and 
the trial was undertaken in accordance with the provisions of the Good Clinical Practice 
Guidelines.11
Randomisation and masking
From March 27, 2009, until Jan 31, 2011, infants aged 6–12 weeks and children aged 5–17 
months were recruited and randomly assigned (1:1:1) by block randomisation with 
minimisation by centre to one of three groups. One group received RTS,S/AS01 at months 0, 
1, and 2, followed by a booster dose at month 20 (R3R group); a second group received the 
RTS,S/AS01 primary vaccination series with meningococcal serogroup C conjugate vaccine 
(Menjugate, Novartis, Basel, Switzerland) instead of an RTS,S/AS01 booster (R3C group); 
and the third group received only comparator vaccines: rabies vaccine (Verorab, Sanofi 
Pasteur, Paris, France) for children and Menjugate for young infants (C3C [control group]; 
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appendix p 19). Young infants received the study vaccine at the same time as the Expanded 
Program on Immunization vaccines.
Procedures
Participants did not receive malaria treatment before vaccination. The treatment of malaria 
during the study was done in accordance with national guidelines. Malaria was detected by 
passive surveillance. The primary case definition for clinical malaria was an illness 
accompanied by an axillary temperature of at least 37·5°C and P falciparum asexual 
parasitaemia (>5000 parasites per mm3) or a case of malaria meeting the primary case 
definition of severe malaria according to a predefined algorithm (appendix p 46). The 
secondary case definition for clinical malaria was illness accompanied by an axillary 
temperature of at least 37·5°C or reported fever within the past 24 h and P falciparum 
asexual parasitaemia at a density of more than 0 parasites per mm3. The primary case 
definition for severe malaria was P falciparum asexual parasitaemia at a density of more than 
5000 parasites per mm3 with one or more markers of severe disease and without diagnosis of 
a coexisting illness (appendix p 47). The secondary case definition for severe malaria was P 
falciparum asexual parasitaemia at a density of more than 5000 parasites per mm3 with one 
or more markers of severe disease, including cases in which a coexisting illness was present 
or could not be ruled out. Markers of severe disease were prostration, respiratory distress 
(defined as lower chest wall indrawing or abnormally deep breathing), a Blantyre coma 
score of 2 or less (on a scale of 0–5, with higher scores suggesting a higher level of 
consciousness), two or more observed or reported seizures, hypoglycaemia (glucose less 
than 2·2 mmol/L), acidosis (base excess ≤–10·0 mmol/L), raised lactate concentration (≥5·0 
mmol/L), or haemoglobin concentration of less than 50 g/L.12 Coexisting illnesses were 
defined as radiographically proven pneumonia, meningitis established by analysis of 
cerebrospinal fluid, bacteraemia, or gastroenteritis with severe dehydration.
Fatal malaria was defined as a fatal case meeting the International statistical classification of 
diseases and related health problems, tenth edition, categories B50, B53, and B54. All-cause 
hospital admission was defined as a medical hospital admission of any cause, excluding 
planned admissions for medical investigation and care or elective surgery and trauma. All-
cause mortality was defined as a fatality of any cause, including mortality in the community 
and in hospital. Incident severe malaria anaemia was defined as a haemoglobin 
concentration less than 50 g/L and P falciparum asexual parasitaemia at a density of more 
than 0 parasites per mm3. Malaria hospital admission was defined as a hospital admission 
accompanied by P falciparum parasitaemia at a density greater than 5000 parasites per mm3. 
Blood transfusion was defined as a child with inpatient admission with documented blood 
transfusion.
We collected information on all unsolicited reports of adverse events (AEs) that occurred 
within 30 days after vaccination and on local and systemic reactogenicity within 7 days after 
vaccination among the first 200 participants enrolled at each centre, as described in the 
appendix (p 7). Serious AEs (SAEs) were identified during study follow-up by surveillance 
at health facilities in the study area and through monthly home visits. Verbal autopsies using 
standardised procedures were done on deaths that occurred outside hospital. SAEs were 
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coded from clinician-assigned diagnoses according to the preferred terms of the Medical 
dictionary for regulatory activities.13
The case histories of all participants with reported meningitis or other CNS infections or 
inflammation were reviewed by two independent experts and designated as confirmed 
meningitis, not meningitis, or undetermined (appendix pp 7–8). Anti-circumsporozoite 
antibodies were measured by ELISA in the first 200 participants in each age category at 
each study site at enrolment; 1 and 18 months after the third dose of vaccine; 1, 12, and 24 
months after the booster dose; and at the last study visit. The threshold for a positive titre 
was 0·5 EU/mL.14 Other laboratory and radiological procedures are described in the 
appendix (pp 9–10).
Outcomes
Analysis of the original coprimary endpoints of the occurrence of malaria up to 12 months 
after dose 3 and other secondary outcomes have been published previously.7–9 In this final 
analysis, we present data for the efficacy of the booster on the occurrence of malaria and 
other disease endpoints that allow the assessment of the public health effect of the vaccine, 
such as VE against anaemia, blood transfusion, hospital admission, mortality, and other 
serious illnesses.
Statistical analysis
All results presented are for the modified intention-to-treat (ITT) population, unless 
otherwise recorded as per protocol. The modified ITT population included all participants 
who received at least one dose of vaccine. The per-protocol population included all 
participants who received three doses of vaccine according to protocol and contributed to the 
efficacy surveillance starting 14 days after the third dose. Efficacy against all episodes of 
malaria was analysed by negative binomial regression with follow-up time as offset, 
allowing for interdependence between episodes within the same participant. Overall 
estimates were adjusted for study site as a fixed effect, whereas site estimates were 
unadjusted for covariates. Inter-site variation was assessed by site interaction terms. VE over 
time was assessed by calculating VE during consecutive time periods, months 0–20, months 
21–32, and month 33 to study end. The incremental efficacy of the RTS,S/AS01 booster 
dose was calculated for the time period after month 20, when the booster dose was 
administered, and was calculated as 1 minus the incident rate ratio between the R3R and 
R3C groups. VE against severe endpoints (ie, severe malaria, malaria hospital admission, 
fatal malaria, all-cause hospital admission, all-cause mortality, incident severe anaemia, and 
blood transfusion) was estimated as a relative risk reduction with Fisher’s exact p values. 
The number of cases averted over time was calculated as the sum of 3-monthly differences 
in the estimated number of cases between the control and the RTS,S/AS01 groups (R3R and 
R3C combined up to the time of booster dose and R3R and R3C separately after the booster 
dose) and expressed per 1000 participants vaccinated. 14 days after an episode were 
subtracted from the time at risk and no malaria events were counted during this period. 95% 
CIs were estimated by bootstrapping, using the 2·5 and 97·5 centiles of 1000 replicates 
obtained by sampling participants, stratified by site.15 The primary case definition of 
clinical malaria was used for calculation of VE, whereas a more sensitive secondary case 
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definition was used for the assessment of the number of cases averted of clinical malaria 
because, in clinical practice, sick children who present to a health facility with any level of 
malaria parasitaemia are likely to receive treatment for malaria. Data were censored at the 
end of the follow-up period or at the date of emigration, withdrawal of consent, or death. p 
values less than 0·05 were deemed significant.
This trial is registered with ClinicalTrials.gov, number NCT00866619.
Role of the funding source
GSK Biologicals SA were involved in study design, and coordinated data collection, data 
analysis, data interpretation, and writing of the report. The PATH Malaria Vaccine Initiative 
(MVI) contributed to study design and data interpretation, but were not involved in data 
collection, data analysis, or writing of the report. The RTS,S Clinical Trials Partnership had 
full access to all the data in the study and had final responsibility for the decision to submit 
for publication.
Results
8922 children and 6537 young infants were enrolled and included in the modified ITT 
analyses; of these, 6918 (78%) children and 5997 (92%) young infants were included in the 
per-protocol analyses (figures 1 and 2). The median follow-up after dose 1 in the 6–12 
weeks age group was 37·8 months (IQR 34·3–41·0) in R3R, 37·7 months (34·1–41·1) in 
R3C, and 37·8 months (34·1–41·1) in C3C (median overall 37·7 months, (IQR 34·1–41·1; 
modified ITT). The median follow-up after dose 1 in the 5–17 months age group was 48·1 
months (IQR 36·7–50·1) in R3R, 48·1 months (37·9–50·1) in R3C, and 48·4 months (41·3–
50·1) in C3C (median overall 48·2 months, IQR 39·4–50·1; modified ITT). Baseline 
characteristics were similar in the three study groups in each age category and between the 
modified ITT and per-protocol populations, but differed between sites (appendix p 20). 
Insecticide-treated bednet use was consistently high, although it varied between study sites 
(appendix p 25). Malaria incidence in young infants in the C3C group during the first 12 
months of follow-up ranged across sites from 0·03 to 4·27 episodes per infant per year (per 
protocol; appendix p 48). Artemisinin combination therapy was the first-line antimalarial 
and was given to treat 99% of malaria cases (42 353 of 42 977 episodes in children and 29 
012 of 29 257 episodes in infants; appendix p 25). 158 of 8922 (1·8%, 95% CI 1·5–2·1) 
children and 148 of 6537 (2·3%, 1·9–2·7) young infants died during follow-up (month 0 to 
study end; appendix pp 49, 59).
In the modified ITT population, from month 0 until study end, compared with 9585 episodes 
of clinical malaria that met the primary case definition in children in the C3C group, 6616 
episodes occurred in children in the R3R group (VE 36·3%, 95% CI 31·8–40·5) and 7396 in 
the R3C group (28·3%, 23·3–32·9; table 1; appendix pp 28, 69). Corresponding data in the 
per-protocol population were 8352 episodes in the C3C group compared with 5691 in the 
R3R group (VE 39·0%, 95% CI 34·3–43·3) and 6597 in the R3C group (26·2%, 20·8–31·2; 
appendix p 67). Efficacy was similar in children vaccinated when 5–11 months of age or 12–
17 months of age (appendix p 71). Efficacy varied by site with or without booster 
vaccination, but these differences were not significant (pinteraction=0·09 and pinteraction=0·11, 
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respectively; figure 3). Efficacy waned over time, and in the R3C group it was no longer 
detectable in the last study period (VE month 33 to study end 2·9%, 95% CI –6·4 to 11·4; 
table 1; appendix p 29). By contrast, VE persisted to study end in the R3R group (VE month 
33 to study end 12·3%, 95% CI 3·6–20·1; table 1 and appendix p 29). The incremental 
efficacy provided by the booster dose during the 12 months after booster vaccination was 
25·6% (95% CI 18·2–32·3; table 1 and appendix p 30).
In the modified ITT population, from month 0 until study end, compared with 171 children 
in the C3C group, 116 children in the R3R group (VE 32·2%, 95% CI 13·7 to 46·9) and 169 
in the R3C group (1·1%, –23·0 to 20·5) experienced at least one episode of severe malaria 
that met the primary case definition (table 2; appendix p 69). Corresponding data in the per-
protocol population were 135 children affected in the C3C group compared with 94 in the 
R3R group (VE 28·5%, 95% CI 6·3 to 45·7) and 141 in the R3C group (–5·8%, –35·0 to 
17·0; appendix p 67). From month 0 until month 20, 156 children in the combined R3R plus 
R3C group experienced severe malaria compared with 118 in the C3C group (VE 33·9%, 
95% CI 15·3–48·3); however, from month 21 to study end, compared with 62 children in the 
C3C group, 64 in the R3R group (VE –4·0%, 95% CI –50·0 to 27·8) and 88 in the R3C 
group (–41·0%, –98·5 to –0·8; table 2) experienced severe disease. Figures 3C and D show 
VE against severe malaria by site over the study period (month 0 to study end); although not 
significant, there is a pattern for the higher point estimates of VE to occur in the lower 
transmission settings as is the case for VE against clinical malaria and negative point 
estimates (with large CIs) to occur in the R3C high transmission areas. The appendix (p 31) 
shows the distribution of markers of severe malaria in the three study groups; illnesses 
characterised by a low coma score seemed to occur more frequently in children who had 
received RTS,S/AS01, but confidence intervals overlap. 598 (97%) of 618 children and 409 
(98%) of 418 young infants admitted with severe malaria recovered without major lasting 
sequelae (appendix pp 72–73).
From month 0 until study end, compared with 44 children in the C3C group, 23 children in 
the R3R group (VE 47·8%, 95% CI 11·6 to 69·9) and 34 in the R3C group (22·7%, –23·8 to 
52·1) had at least one episode of incident severe malaria anaemia; and compared with 347 
children in the C3C group, 227 children in the R3R group (34·6%, 22·5 to 44·9) and 286 in 
the R3C group (17·5%, 3·3 to 29·7) were admitted to hospital for malaria at least once 
(appendix p 74–76). Compared with 771 children in the C3C group, 644 children in the R3R 
group (VE 16·5%, 7·2–24·9) and 682 in the R3C group (11·5%, 1·7–20·3) were admitted to 
hospital at least once for any cause (appendix p 76). Between month 0 and study end, 
compared with 109 controls, 78 children in the R3R group (VE 28·5%, 95% CI 3·5 to 47·2) 
and 91 in the R3C group (16·5%, –11·4 to 37·5) had at least one blood transfusion (appendix 
p 76).
Significant efficacy against prevalent parasitaemia was noted in the R3R group compared 
with the C3C group at the cross-sectional assessments at month 32 (p<0·0001), month 44 
(p=0·019), and study end (early p=0·018 and late p=0·044), and in the R3C group at month 
32 (p=0·0001), but not at study end (appendix p 78). No significant VE was noted against 
incident bacteraemia, pneumonia, all-cause mortality, or malaria mortality (appendix pp 74–
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76) and there was no effect on indices of malnutrition with or without a booster dose 
(appendix p 80).
From month 0 until study end, 1774 cases of clinical malaria per 1000 children (95% CI 
1387–2186; range across sites 205–6565) were averted in the R3R group and 1363 per 1000 
children (95% CI 995–1797; range 215–4443) in the R3C group (table 3; figure 4; appendix 
p 83). The numbers of cases averted per 1000 children in the R3R group and R3C group, 
respectively, were 19 (95% CI 4 to 35) and eight (–9 to 26) for severe malaria, 40 (19 to 64) 
and 26 (4 to 51) for malaria hospital admission, 59 (18 to 103) and 41 (0 to 84) for all-cause 
hospital admission, 11 (1 to 24) and nine (–3 to 21) for severe anaemia, and 15 (1 to 31) and 
13 (–1 to 28) for blood transfusions (table 3). The number of cases of clinical and severe 
malaria averted varied substantially by study site; the highest numbers of cases of clinical 
malaria averted were noted in areas of high malaria incidence, such as Siaya, Kenya, and 
Nanoro, Burkina Faso (figure 4A).
In the modified ITT population, from month 0 until study end, compared with 6170 episodes 
of clinical malaria that met the primary case definition in young infants in the C3C group, 
4993 episodes occurred in the R3R group (VE 25·9%, 95% CI 19·9–31·5) and 5444 in the 
R3C group (18·3%, 11·7–24·4; table 1; appendix pp 33, 86). Corresponding data in the per-
protocol population were 5666 episodes in the C3C group compared with 4532 in the R3R 
group (VE 26·7%, 95% CI 20·5–32·4) and 5072 in the R3C group (18·2%, 11·4–24·5; 
appendix p 84). Estimates of VE across sites ranged from –14·6% to 50·4% in the R3R 
group and from –2·8% to 33·6% in the R3C group (figure 5). Efficacy waned over time, but, 
compared with the C3C group, was still present in the R3R group during the last study 
period (VE month 33 to study end 10·5%, 95% CI 0·2 to 19·7), but not in the R3C group 
(4·4%, –6·7 to 14·3; table 1; appendix p 34). The incremental efficacy against clinical 
malaria provided by the booster dose during the 12 months after booster vaccination was 
22·3% (95% CI 14·0–29·8; table 1; appendix p 35).
In the modified ITT population, from month 0 to study end, compared with 116 young 
infants in the C3C group, 96 young infants in the R3R group (VE 17·3%, 95% CI –9·4 to 
37·5) and 104 in the R3C group (10·3%, –17·9 to 31·8) experienced at least one episode of 
severe malaria that met the primary case definition (table 2). Compared with 35 young 
infants in the C3C group, 24 young infants in the R3R group (VE 31·5%, 95% CI –18·5 to 
61·0) and 31 in the R3C group (11·4%, –47·9 to 47·2) had at least one episode of incident 
severe malaria anaemia (appendix pp 88). Compared with 188 young infants in the C3C 
group, 142 young infants in the R3R group (VE 24·5%, 95% CI 5·6 to 39·7) and 167 in the 
R3C group (11·1%, –10·1 to 28·3) were admitted to hospital at least once for malaria 
(appendix p 88). No protection was noted against all-cause hospital admission, bacteraemia, 
pneumonia, all-cause mortality, or malaria mortality (appendix p 88–90). VE did not differ 
between the control and RTS,S/AS01 vaccine with or without a booster groups in terms of 
prevalent parasitaemia or indices of malnutrition (appendix p 92–93).
Between month 0 and study end, the number of cases averted per 1000 young infants in the 
R3R and R3C study groups, respectively, were 983 (95% CI 592–1337; range across sites –
30 to 3406) and 558 (95% CI 158–926; range –172 to 2178) for clinical malaria, 12 (–6 to 
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32) and eight (–13 to 28) for severe malaria, 18 (–8 to 42) and 14 (–13 to 39) for malaria 
hospital admissions, and 36 (–17 to 90) and 24 (–27 to 82) for all-cause hospital admissions 
(figure 6; table 3; appendix p 94).
Anti-circumsporozoite antibody responses are shown in the appendix (p 36). 1 month after 
the booster dose with RTS,S/AS01, the geometric mean titre in children in the R3R group 
was 318·2 EU/mL (95% CI 295·1–343·0) compared with 34·2 EU/mL (30·5–38·3) in the 
R3C group (per-protocol population; appendix p 95). The comparable data in young infants 
were 169·9 EU/mL (95% CI 153·8–187·7) and 6·2 EU/mL (5·4–7·0), respectively (per-
protocol population; appendix p 96). Antibody concentrations fell after the increase induced 
by the booster dose and 12 months later were 52·4 EU/mL (95% CI 47·8–57·6) in the R3R 
group and 19·3 EU/mL (17·2–21·8) in the R3C group in children and 15·9 EU/mL (13·8–
18·3) in the R3R group and 3·7 EU/mL (3·3–4·2) in the R3C group in young infants 
(appendix pp 36, 95–96). Anti-circumsporozoite antibodies were categorised by tertile. 
Infants who were RTS,S/AS01 vaccine recipients and whose antibody response was in the 
top tertile 1 month after primary vaccination series had a 36·9% (95% CI 17·3–51·8; 
p=0·0009) reduction in risk of subsequent malaria episodes compared with those in the 
lowest tertile. No significant risk reduction was noted in children in the highest tertile 
compared with those in the lowest tertile (3·6% reduction, 95% CI –25·6 to 26·0; p=0·79; 
appendix pp 37–39).
The RTS,S/AS01 booster dose was more reactogenic than the comparator vaccine in both 
children and young infants, with a higher frequency of both systemic and local reactions 
within 7 days of vaccination in the R3R group than in the R3C or C3C groups (appendix p 
97–98). However, grade 3 reactions were rare, except for grade 3 fevers (>39°C), which 
occurred in 34 of 641 children (5·3%, 95% CI 3·7–7·3) and nine of 608 infants (1·5%, 0·7–
2·8) after a booster dose of RTS,S/AS01 (appendix pp 41, 97–98). The incidence of 
generalised convulsive seizures within 7 days of a booster dose in children was 2·5 per 1000 
doses in the R3R group, 1·2 per 1000 doses in the R3C group, and 0·4 per 1000 doses in the 
C3C group, and in young infants it was 2·2 per 1000 doses in the R3R group, 0·0 per 1000 
doses in the R3C group, and 0·5 per 1000 doses in the C3C group (appendix p 99).
The incidence of SAEs overall and of unsolicited AEs within 30 days of booster vaccination 
were similar in all three study groups (appendix pp 49, 59, 100–103). Meningitis was 
reported as a SAE in 22 children: 11 in the R3R group, ten in the R3C group, and one in the 
C3C group (appendix pp 49, 59). Five of these 22 cases were reported after booster 
vaccination: two in the R3R group and three in the R3C group. A bacterial cause was 
identified in ten cases (five meningococcal, three Haemophilus influenzae, one 
pneumococcal, and one tuberculosis), all in children in the R3R or R3C groups. Meningitis 
was reported as a SAE in 18 young infants; no imbalance in cases of meningitis was noted in 
the younger age group (five cases in the R3R group, seven in the R3C group, and six in the 
C3C group). Meningitis cases were not temporally related to vaccination (appendix p 42). 
Most study sites reported one to three cases of meningitis, but 15 cases were reported from 
Lilongwe, Malawi, and five from Kombewa, Kenya. All cases of meningitis and other 
infections of the nervous system reported as a SAE were reviewed by two independent 
experts. In children, 33 episodes were reviewed by the experts, who classified 12 as 
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confirmed cases of meningitis (six in R3R and six in R3C), 11 as not a meningitis case (five 
in R3R, four in R3C, and two in C3C), and ten as undetermined (five in R3R, two in R3C, 
and three in C3C). In infants, 22 episodes were reviewed by the experts, who classified 11 as 
confirmed cases of meningitis (three in R3R, five in R3C, and three in C3C), eight as not 
meningitis cases (two in R3R, two in R3C, and four in C3C), and three as undetermined 
(two in R3R and one in R3C).
Discussion
The decrease in efficacy of RTS,S/AS01 against clinical and severe malaria over time since 
vaccination, which was reported previously,9 continued during the extended follow-up 
period in both children and infants who did not receive a booster dose of vaccine. 
Nevertheless, VE against clinical malaria during the full follow-up period in the absence of a 
booster dose were about 28% in children and 18% in young infants, which resulted in a 
substantial reduction in the number of cases of clinical malaria. Protection against clinical 
malaria was prolonged in both children and young infants by a booster dose, which 
increased the number of cases prevented across sites in both children and young infants. The 
proportional increase in efficacy against clinical malaria associated with booster vaccination 
was similar in children and young infants, but efficacy after the booster dose remained lower 
in those who received their primary vaccination when aged 6–12 weeks rather than at the 
age of 5–17 months. No significant efficacy against severe malaria was noted during the 
study period in young infants or children who did not receive a booster dose of vaccine. This 
finding contrasts with our earlier report of a significant reduction in severe malaria in 
children in the older age category who were followed up until the time of booster 
vaccination.8,9 This anomaly can be explained by the higher risk of severe malaria from 
month 21 until the end of the trial in children who did not receive a booster dose compared 
with children in the control group, whereas this was not noted in children who received a 
booster dose of vaccine. This increased risk occurred predominantly in sites with a higher 
level of malaria transmission. Why children who received the RTS,S/AS01 primary 
vaccination series but who did not receive a booster dose were at increased risk of severe 
malaria during the latter part of the study is uncertain. This finding might have occurred by 
chance; the number of cases was low and a similar pattern was not noted for cases of 
uncomplicated malaria. However, vaccination, by providing protection against malaria 
infection, might have reduced the natural acquisition of immunity obtained through repeated 
infections, making these children more susceptible when the vaccine effect waned. This 
possibility needs to be explored in further studies, and ongoing surveillance of study 
participants is taking place at three centres. The increased risk for severe malaria in the older 
age category was reduced by the administration of a booster dose of RTS,S/AS01. This 
finding suggests that if a decision is made to implement RTS,S/AS01 in an age category 
similar to that of the older children recruited to this trial, then consideration should be given 
to inclusion of a booster dose, especially in higher transmission areas, and the possible effect 
of administration of further booster doses will need to be explored.
Vaccination with RTS,S/AS01 significantly reduced overall hospital admissions, admissions 
because of malaria, severe anaemia, and the need for blood transfusion in children, with 
these protective effects being more marked in those who received a booster dose. The 
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numbers of cases averted of these endpoints were lower in infants vaccinated at age 6–12 
weeks. No significant effect on overall mortality, malaria mortality, pneumonia, or sepsis 
was noted in either age category. The latter finding is surprising because malaria seems to be 
an important risk factor for invasive bacterial infections.16 Failure to detect an effect of 
RTS,S/AS01 on these secondary outcomes, including mortality, might have been caused in 
part by the high level of clinical care provided during the trial, including high coverage with 
insecticide-treated bednets and enhanced access to effective treatment of malaria and other 
disorders. RTS,S/AS01 might have reduced the numbers of cases averted of these endpoints 
even more in communities where access to a high level of clinical care is less readily 
accessible than was the case during the trial.
Administration of a booster dose of RTS,S/AS01 led to an increase in anti-circumsporozoite 
geometric mean titres in both young infants and children, as noted previously in adults 
immunised with an earlier formulation of the vaccine (RTS,S/AS02),17 but the anti-
circumsporozoite geometric mean titres after the booster remained lower than concentrations 
after the primary course and the booster effect was only transitory. Changes in anti-
circumsporozoite concentration over time paralleled changes in efficacy against clinical 
malaria. No previously unvaccinated children vaccinated with a single dose of RTS,S/AS01 
at the same age as the children who received the booster dose were included in the trial, so 
we cannot conclude definitively that children who received the booster dose had acquired 
immunological memory. However, limited data from a previous study18 suggest that the 
antibody response to a booster dose in children who had been primed with RTS,S/AS01 was 
greater than that reported in participants who had received a single dose without priming, 
and that some immunological memory had been induced with the prime series of RTS,S/
AS01 vaccination. Further studies are needed to define the mechanism of memory induced 
with RTS,S/AS01 and whether there are ways in which this could be improved.
SAEs were reported in about a quarter of children in the trial, with a similar incidence in all 
study groups, but only 0·3% were judged to be vaccine related (appendix pp 49, 59). 
However, the significant imbalance in cases of meningitis in children vaccinated at the age 
of 5–17 months between the RTS,S/AS01 and control groups, reported previously,9 
remained. Five new cases of meningitis were recorded from month 21 until the end of the 
trial in children in the RTS,S/AS01 groups, but none occurred in the control group; two of 
the five new cases occurred in children who had received the booster dose of RTS,S/AS01 
and three in children who had received the control meningococcal serogroup C vaccine. The 
imbalance in cases of meningitis was not noted in young infants. This imbalance in cases of 
meningitis in children could be a chance finding because comparisons were made across 
groups for many different diagnostic classifications of SAEs, most of the cases were 
clustered in two sites, and there was no temporal relation to vaccination. If children who 
received RTS,S/AS01 do have an increased risk of meningitis, the mechanism that could 
have brought this about is difficult to understand. If RTS,S/AS01 is licensed, post-
registration studies will be done to establish the significance of this finding. The incidence of 
fever in the 1 week after vaccination was higher in both infants and children who received a 
booster dose of RTS,S/AS01 vaccine than in those who received the control vaccine, as 
noted during the primary series of vaccination, and a small number of these febrile reactions 
were accompanied by generalised convulsive seizures.
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Despite its large size and attention to detail, this trial has some weaknesses. The per-protocol 
population was high in young infants but lower in children because of a loss of data from 
one centre after administration of vaccine affected by a temperature deviation. At one centre 
(Bagamoyo, Tanzania), there was a concern about the quality of the work of two field 
workers assigned to undertake monthly home visits, but further investigation found no 
evidence that this had led to under-reporting of SAEs. Differences in the effect of RTS,S/
AS01 were found between study sites, but because of the infrequency of assessment of some 
of the trial endpoints, including severe malaria, site-to-site comparisons should be made with 
caution. The detailed study analyses done at several timepoints generated many hundreds of 
comparisons and created the opportunity for some unexpected associations to emerge by 
chance. Finally, the high standard of care provided to all trial participants might have limited 
the ability of the trial to detect an effect on mortality or other severe outcomes.
An application for a Committee for Medicinal Products for Human Use (CHMP) scientific 
opinion on RTS,S/AS01 through the European Medicines Agency Article 58 procedure is 
under review. If a positive scientific opinion is obtained from the CHMP and the vaccine is 
prequalified by WHO, malaria-endemic countries will need to decide whether to license and 
use RTS,S/AS01 and, if so, what schedule to use. In anticipation of a positive opinion from 
the CHMP, WHO has established a Joint Technical Expert Group19 to monitor progress 
with the RTS,S/AS01 trials with the intention that this group will provide advice to a joint 
committee of WHO’s Malaria Policy Advisory Committee and the Strategic Advisory 
Group of Experts committees, which will formulate WHO’s recommendations on the use of 
RTS,S/AS01. The results provided in this phase 3 trial should help these groups in making 
their decisions and, if RTS,S/AS01 is licensed in African countries, help national malaria 
control programmes in deciding how best to use this vaccine, which, if used correctly, has 
the potential to prevent millions of cases of malaria.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The trial was sponsored by GlaxoSmithKline Biologicals SA and was funded by both GSK Biologicals SA and the 
PATH MVI. All centres received a grant from the MVI for running the trial. Author travel and accommodation 
related to this trial were financed by the MVI. GlaxoSmithKline Biologicals SA received a grant from the MVI to 
run the trial. The MVI received a grant from the Bill & Melinda Gates Foundation to run this trial and to 
compensate MVI authors for trial-related travel. GSK Biologicals SA developed and manufactured the vaccine. The 
opinions and assertions herein are the views of The RTS,S Clinical Trials Partnership and not the Department of 
Defense or US Government. We thank A Gervaix (University of Geneva, Geneva, Switzerland) and C Newton 
(University of Oxford, Oxford, UK) for reviewing the case histories of all participants with reported meningitis or 
other CNS infections or inflammation. The findings and conclusions in this report are those of The RTS,S Clinical 
Trials Partnership and do not necessarily represent the official position of the Centers for Disease Control and 
Prevention.
RTS,S Clinical Trials Partnership members 
Burkina Faso and Belgium H Tinto, U D’Alessandro, H Sorgho, I Valea, M C Tahita, W 
Kabore, F Kiemde, P Lompo, S Ouédraogo, K Derra, F Ouédraogo, J B Ouédraogo (Institut 
de Recherche en Science de la Santé, Nanoro; and Institute of Tropical Medicine, Antwerp). 
Page 12













Belgium W R Ballou, J Cohen, Y Guerra, D Heerwegh, E Jongert, D Lapierre, A Leach, M 
Lievens, O Ofori-Anyinam, A Olivier, J Vekemans (GlaxoSmithKline Vaccines, Wavre). 
Gabon and Germany S T Agnandji, B Lell, J F Fernandes, B P Abossolo, A L Kabwende, A 
A Adegnika, B Mordmüller, S Issifou, P G Kremsner, M M Loembe, E Bache, A Alabi 
(Albert Schweitzer Hospital, Lambaréné; and Institute of Tropical Medicine, University of 
Tübingen, Tübingen). Ghana and UK S Owusu-Agyei, K P Asante, O Boahen, D Dosoo, I 
Asante, Z Yidana, J Anim, E Adeniji, A K Yawson, K Kayan, D Chandramohan, B 
Greenwood (Kintampo Health Research Center, Kintampo; and London School of Hygiene 
& Tropical Medicine, London). Ghana D Ansong, T Agbenyega, S Adjei, H O Boateng, T 
Rettig, J Sylverken, D Sambian, A Badu-Prepah, A Kotey, P Buabeng, V Paintsil, A Enimil 
(School of Medical Sciences, Kumasi). Kenya and USA M J Hamel, S Kariuki, M Oneko, C 
Odero, K Otieno, N Awino, V Muturi-Kioi, J Omoto, T Sang, S Odhiambo, K F Laserson, L 
Slutsker (KEMRI/CDC Research and Public Health Collaboration, Kisumu, Kenya, and 
Atlanta, GA, USA); W Otieno, L Otieno, N Otsyula, S Gondi, J Ochola, G Okoth, D C 
Mabunde, A Wangwe, A Otieno, J Oyieko, J Cowden, B Ogutu (KEMRI–Walter Reed 
Project, Kombewa, Kenya, and Silver Springs, MD, USA). Kenya P Njuguna, K Marsh, P 
Akoo, C Kerubo, C Maingi, P Bejon, A Olotu, R Chilengi, B Tsofa, T Lang, J Gitaka, K 
Awuondo (KEMRI–Wellcome Trust Research Program, Kilifi, Kenya). Malawi and USA F 
Martinson, I Hoffman, T Mvalo, P Kamthunzi, R Nkomo, T Tembo, G Tegha, C Chawinga, 
T Banda, S Khan, S Mwambakulu, E Mzembe (University of North Carolina Project, 
Lilongwe, Malawi, and Chapel Hill, NC, USA). Mozambique and Spain J Sacarlal, P Aide, 
L Madrid, S Mandjate, J J Aponte, H Bulo, S Massora, E Varela, E Macete, P Alonso 
(Centro de Investigação em Saúde de Manhiça, Manhiça; and ISGlobal, Barcelona Centre 
for International Health Research [CRESIB], Hospital Clínic, Universitat de Barcelona, 
Barcelona). Tanzania and Denmark J Lusingu, S Gesase, A Malabeja, O Abdul, C Mahende, 
E Liheluka, M Lemnge, T G Theander, C Drakeley, J Mbwana, R Olomi, B Mmbando 
(National Institute for Medical Research, Korogwe; and University of Copenhagen, 
Copenhagen). Tanzania and Switzerland S Abdulla, N Salim, A Mtoro, S Ahmed, A Hamad, 
S Kafuruki, R Minja, M Tanner, M Maganga, A Mdemu, C Gwandu, A Mohammed (Ifakara 
Health Institute, Bagamoyo; Swiss Tropical and Public Health Institute, Basel). USA D 
Kaslow, D Leboulleux, B Savarese, D Schellenberg (PATH MVI, Washington, DC).
References
1. WHO. World Malaria Report, 2014. Geneva: World Health Organization; 2014. 
2. Gordon DM, McGovern TW, Krzych U, et al. Safety, immunogenicity, and efficacy of a 
recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface 
antigen subunit vaccine. J Infect Dis. 1995; 171:1576–85. [PubMed: 7769295] 
3. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein 
to the RTS,S/AS candidate vaccine. Hum Vacc. 2010; 6:90–96.
4. Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of 
falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, 
efficacy, and immunologic associates of protection. J Infect Dis. 2009; 200:337–46. [PubMed: 
19569965] 
5. Lell B, Agnandji S, von Glasenapp I, et al. A randomized trial assessing the safety and 
immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in 
Gabon. PLoS One. 2009; 4:e7611. [PubMed: 19859560] 
Page 13













6. Owusu-Agyei S, Ansong D, Asante K, et al. Randomized controlled trial of RTS,S/AS02D and 
RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian 
children. PLoS One. 2009; 4:e7302. [PubMed: 19806184] 
7. RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. 
N Engl J Med. 2012; 367:2284–95. [PubMed: 23136909] 
8. RTS,S Clinical Trials Partnership. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in 
African children. N Engl J Med. 2011; 365:1863–75. [PubMed: 22007715] 
9. RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 
months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 
African sites. PLoS Med. 2014; 11:e1001685. [PubMed: 25072396] 
10. Leach A, Vekemans J, Lievens M, et al. Design of a phase III multicenter trial to evaluate the 
efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in 
Africa. Malar J. 2011; 10:224. [PubMed: 21816029] 
11. ICH harmonised tripartite guideline. Guideline for good clinical practice; International Conference 
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; 
1996. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/
E6_R1_Guideline.pdf
12. Molyneux ME, Taylor TE, Wirima JJ, Borgstein A. Clinical features and prognostic indicators in 
paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med. 1989; 71:441–
59. [PubMed: 2690177] 
13. ICH. [accessed April 22, 015] MedDRA® term selection: points to consider. ICH-endorsed guide 
for MedDRA users. 2013. https://www.meddra.org/sites/default/files/guidance/file/
9491-1610_termselptc_r4.6_sep2013.pdf
14. Clement F, Dewar V, Van Braeckel E, et al. Validation of an enzyme-linked immunosorbent assay 
for the quantification of human IgG directed against the repeat region of the circumsporozoite 
protein of the parasite Plasmodium falciparum. Malar J. 2012; 11:384. [PubMed: 23173602] 
15. Efron, B., Tibshirani, R. An introduction to the bootstrap. New York: Chapman & Hall; 1993. 
16. Scott JA, Berkley JA, Mwangi I, et al. Relation between falciparum malaria and bacteraemia in 
Kenyan children: a population based, case-control study and a longitudinal study. Lancet. 2011; 
378:1316–23. [PubMed: 21903251] 
17. Bojang K, Milligan P, Pinder M, et al. Five-year safety and immunogenicity of GlaxoSmithKline’s 
candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living 
in a malaria-endemic region of The Gambia. Hum Vaccin. 2009; 5:242–47. [PubMed: 19276646] 
18. Kester K, Cummings J, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of 
falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, 
efficacy, and immunologic associates of protection. J Infect Dis. 2009; 200:337–46. [PubMed: 
19569965] 
19. WHO. [accessed April 22, 2015] WHO Initiative for vaccine research/global malaria programme 
joint technical expert group (JTEG) on malaria vaccines entering pivotal phase 3 trials & beyond 
(established April 2009). http://www.who.int/immunization/research/committees/jteg/en
Page 14














Evidence before this study
We did a systematic literature search between Dec 18, 2014, and Feb 20, 2015, of 
randomised controlled trials of RTS,S malaria vaccine on PubMed, the Cochrane Library, 
and other relevant data sources for the period 1984 to Jan 31, 2015. We searched PubMed 
using the Medical Subject Headings (MeSH) terms “RTS,S-AS01B vaccine”[All Fields] 
OR “RTS,S-AS01E vaccine”[All Fields] OR “RTS,S-AS02A vaccine”[All Fields] OR 
“RTS,S-AS02D vaccine”[All Fields] OR “RTS,S/AS01”[All Fields] OR “RTS,S/AS02”
[All Fields] AND “clinical trial”[Publication Type] OR “clinical trials as topic”[MeSH 
Terms] OR “clinical trial”[All Fields] AND “humans”[MeSH Terms]. For the Cochrane 
Library and other data sources, we used the following key search terms: “RTS,S”, 
“malaria vaccines”, AND “clinical trials”. The 60 manuscripts identified included five 
that reported the results of randomised controlled trials with long-term safety or efficacy 
follow-up or booster dose, two pooled analyses, and two systematic reviews.
Added value of this study
This study provided additional information on the safety and long-term efficacy of 
RTS,S/AS01 in a large population of children across different malaria transmission 
settings. Additionally, the study showed how booster vaccination extended the period of 
protection provided by the vaccine.
Implications of all available evidence
The RTS,S malaria vaccine candidate has consistently shown protection against clinical 
malaria episodes in different age groups across different transmission settings. Vaccine 
efficacy has been shown with or without concurrent Expanded Program on Immunization 
vaccination. The vaccine has consistently shown a good safety profile, although a 
meningitis safety signal reported among older children will need further follow-up. The 
results of the present study show the potential public health benefit of the RTS,S vaccine 
as an additional means for malaria control whilst the next generation of malaria vaccines 
are being developed.
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Figure 1. Trial profile for participants aged 5–17 months
Participants’ flow in the study in those enrolled in the 5–17 months age category. 
ITT=intention to treat. *For 70 children, the screening data had not been reported before the 
database freeze of the previous analyses and these participants were not included in the 
CONSORT charts published previously. †During monitoring, one participant was found to 
have been enrolled twice at two different clinics under two different participant numbers. 
This participant was excluded from the per-protocol analyses. Because of the removal of one 
participant number from the database, the total number of participants enrolled into the 
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study changed from 15 460 (8923 in the 5–17 months age group), as reported in previous 
analyses, to 15 459 participants (8922 in the 5–17 months age group) in the final analyses 
reported here. ‡2867 children in the with booster group, 2887 in the without booster group, 
and 2905 in the control group received doses 1 and 2.
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Figure 2. Trial profile for participants aged 6–12 weeks
Participants’ flow in the study in those enrolled in the 6–12 weeks age category. 
ITT=intention to treat. *For 118 infants, the screening data had not been reported before the 
database freeze of the previous analyses and these participants were not included in the 
CONSORT charts published previously. †2115 children in the with booster group, 2119 in 
the without booster group, and 2134 in the control group received doses 1 and 2. ‡For some 
participants, consent to the extension occurred before visit 34. One participant consented to 
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the extension but died before visit 34. This participant is considered as enrolled into the 
extension and the reason for not undertaking visit 38 is recorded as died.
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Figure 3. Vaccine efficacy against clinical and severe malaria by study site in the 5–17 months 
age category
VE against all episodes of clinical malaria (primary case definition) in (A) the R3C group 
and (B) the R3R group from month 0 to study end; and VE against severe malaria (primary 
case definition) in (C) the R3C group and (D) the R3R group from month 0 to study end. 
Study sites are ordered from lowest (Kilifi) to highest (Siaya) incidence of clinical malaria 
(secondary case definition) measured in control infants 6–12 weeks of age at enrolment 
during 12 months of follow-up. pinteraction not calculated for (C) or (D). Analyses were by 
modified intention to treat. Bars are 95% CIs. The size of each square is proportional to the 
number of participants enrolled at each study site. The following numbers of children aged 
5–17 months were enrolled by site for all three groups (R3R, R3C, and C3C) together: 600 
in Kilifi, 912 in Korogwe, 1002 in Manhiça, 704 in Lambaréné, 903 in Bagamoyo, 800 in 
Lilongwe, 600 in Agogo, 1000 in Kombewa, 1002 in Kintampo, 600 in Nanoro, and 799 in 
Siaya. R3C=RTS,S/AS01 primary schedule without booster. C3C=control group. 
R3R=RTS,S/AS01 primary schedule with booster. VE=vaccine efficacy.
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Figure 4. Cases of clinical and severe malaria averted at each site during 48 months of follow-up 
in the 5–17 months age category
Analyses were by modified intention to treat. Data are ordered by increasing malaria 
incidence at each study site. Cases averted of (A) clinical malaria (secondary case definition) 
and (B) severe malaria (secondary case definition) between month 0 and study end. The 
secondary case definition of severe malaria was used for this analysis because, during 
routine clinical practice, these children would normally receive a full course of antimalarial 
treatment. R3C=RTS,S/AS01 primary schedule without booster. R3R=RTS,S/AS01 primary 
schedule with booster.
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Figure 5. Vaccine efficacy against clinical and severe malaria by study site in the 6–12 weeks age 
category
VE against all episodes of clinical malaria (primary case definition) in (A) the R3C group 
and (B) the R3R group from month 0 to study end; and VE against severe malaria (primary 
case definition) in (C) the R3C group and (D) the R3R group from month 0 to study end. 
Study sites are ordered from lowest (Kilifi) to highest (Siaya) modified incidence of clinical 
malaria (secondary case definition) measured in control infants 6–12 weeks of age at 
enrolment during 12 months of follow-up. Analyses were by modified intention to treat. 
Bars are 95% CIs. The size of each square is proportional to the number of participants 
enrolled at each study site. The following numbers of infants aged 6–12 weeks were enrolled 
by site for all three groups (R3R, R3C, and C3C) together: 304 in Kilifi, 593 in Korogwe, 
635 in Manhiça, 226 in Lambaréné, 802 in Bagamoyo, 826 in Lilongwe, 688 in Agogo, 631 
in Kombewa, 331 in Kintampo, 681 in Nanoro, and 820 in Siaya. C3C=control group. 
R3C=RTS,S/AS01 primary schedule without booster. R3R=RTS,S/AS01 primary schedule 
with booster. VE=vaccine efficacy.
Page 22













Figure 6. Cases of clinical and severe malaria averted at each site during 38 months of follow-up 
in the 6–12 weeks age category
Analyses were by modified intention to treat. Data are ordered by increasing malaria 
incidence at each study site. Cases averted of (A) clinical malaria (secondary case definition) 
and (B) severe malaria (secondary case definition) between month 0 and study end. The 
secondary case definition of severe malaria was used for this analysis because, during 
routine clinical practice, these children would normally receive a full course of antimalarial 
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treatment. R3C=RTS,S/AS01 primary schedule without booster. R3R=RTS,S/AS01 primary 
schedule with booster.
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Number of cases averted per 1000 participants in children or young infants immunised 
with a primary vaccination schedule with or without a booster dose
5–17 months age category 6–12 weeks age category
R3C group R3R group R3C group R3R group
Clinical malaria (secondary case definition)*
Months 0–20     963 (807 to 1133)†         ··  518 (341 to 687)†      ··
Months 0–32   1221 (973 to 1483)   1475 (1234 to 1733)  526 (200 to 819)  873 (573 to 1158)
Month 0 to study end‡   1363 (995 to 1797)   1774 (1387 to 2186)  558 (158 to 926)  983 (592 to 1337)
Malaria hospital admission
Months 0–20       42 (28 to 59)†         ··      8 (–9 to 25)†      ··
Months 0–32       32 (13 to 53)       44 (26 to 64)      5 (–17 to 27)    14 (–10 to 35)
Month 0 to study end‡       26 (4 to 51)       40 (19 to 64)    14 (–13 to 39)    18 (–8 to 42)
Severe malaria (secondary case definition)
Months 0–20*       19 (8 to 32)†         ··      5 (–8 to 18)†      ··
Months 0–32       12 (–2 to 27)       20 (7 to 34)      5 (–13 to 24)      9 (–8 to 28)
Month 0 to study end‡         8 (–9 to 26)       19 (4 to 35)      8 (–13 to 28)    12 (–6 to 32)
Fatal malaria
Months 0–20*         0 (–2 to 3)†         ··    –1 (–3 to 2)†      ··
Months 0–32       –1 (–4 to 3)         1 (–2 to 4)    –1 (–5 to 2)    –2 (–5 to 2)
Month 0 to study end‡       –2 (–7 to 2)         1 (–3 to 5)    –3 (–7 to 1)    –2 (–6 to 2)
All-cause hospital admission
Months 0–20*       57 (29 to 88)†         ··    22 (–16 to 60)†      ··
Months 0–32       53 (16 to 92)       64 (29 to 103)    15 (–32 to 70)    38 (–9 to 89)
Month 0 to study end‡       41 (0 to 84)       59 (18 to 103)    24 (–27 to 82)    36 (–17 to 90)
All-cause mortality
Months 0–20*       –1 (–7 to 4)†         ··    –5 (–12 to 3)†      ··
Months 0–32       –3 (–10 to 3)         0 (–7 to 6)    –5 (–13 to 3)    –6 (–14 to 3)
Month 0 to study end‡       –5 (–12 to 3)       –1 (–9 to 6)    –5 (–14 to 4)    –6 (–15 to 3)
Incident severe anaemia
Months 0–20*         8 (1 to 15)†         ··      0 (–8 to 11)†      ··
Months 0–32         9 (0 to 19)       10 (1 to 20)      0 (–13 to 15)      3 (–9 to 16)
Month 0 to study end‡         9 (–3 to 21)       11 (1 to 24)    –1 (–16 to 15)      3 (–11 to 17)














5–17 months age category 6–12 weeks age category
R3C group R3R group R3C group R3R group
Blood transfusion
Months 0–20*       13 (4 to 21)†         ··      1 (–10 to 13)†      ··
Months 0–32       13 (1 to 24)       15 (3 to 27)      2 (–15 to 20)      5 (–9 to 23)
Month 0 to study end       13 (–1 to 28)       15 (1 to 31)      1 (–18 to 19)      4 (–12 to 23)
Data are number of cases averted per 1000 participants (95% CI). Analyses were by modified intention to treat. R3C=RTS,S/AS01 primary 
schedule without booster. R3R=RTS,S/AS01 primary schedule with booster.
*
This definition was used for this analysis because, during routine clinical practice, these children would normally receive a full course of anti-
malarial treatment.
†
The schedule without a booster (R3C) and the schedule with a booster (R3R) were pooled (R3R plus R3C) to calculate the number of cases 
averted.
‡
Median of 48 months after the first dose for the 5–17 months age category and 39 months after the first dose for the 6–12 weeks age category.
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